Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442111 | 0.78 | LMNA (0.39) | LMNAMAPT | |
| SCHEMBL15740737 | 0.78 | LMNA (0.39) | LMNAMAPT | |
| SCHEMBL6018336 | 0.78 | LMNA (0.39) | LMNAMAPT | |
| SCHEMBL16371027 | 0.75 | LMNA (0.37) | LMNAMAPT | |
| SCHEMBL17785721 | 0.73 | LMNA (0.36) | LMNAMAPT | |
| SCHEMBL13035655 | 0.73 | ATM (0.38) | LMNAMAPTL3MBTL1 | |
| SCHEMBL1476498 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL5356449 | 0.70 | LMNA (0.41) | LMNAMAPTCA1CA2CA4 | |
| SCHEMBL7997715 | 0.70 | — | — | |
| SCHEMBL13654288 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059074-A1 | BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-116194446-A | SOS1 inhibitor, pharmaceutical composition containing same and application thereof | 北京泰德制药股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-109661392-A | For treating the mitochondrial inhibitors of proliferative disorder | 巴斯利尔药物国际股份公司 | 2019-04-19 | — | — | CN | disclosed |
| CN-105051044-A | Compounds and their use for modulating hemoglobin | GLOBAL BLOOD THERAPEUTICS INC | 2015-11-11 | — | — | CN | disclosed |
| EP-2382215-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-02 | — | — | EP | disclosed |
| US-20100279997-A1 | ANALGESIC THAT BINDS FILAMIN A | PAIN THERAPEUTICS | 2010-11-04 | — | — | US | disclosed |
| WO-2010076525-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | WO | disclosed |
| EP-1656345-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005021500-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279997-A1 | ANALGESIC THAT BINDS FILAMIN A | FLNA, FLNB, OPRL1 | LMNA 405/4885MAPT 3007/4885CA1 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.